The therapeutic potential of the cannabinoids in neuroprotection

Expert Opinion on Investigational Drugs

Volumn 11, Issue 10, 2002, Pages 1365-1374

  Grundy, Robert I ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cannabinoid; Cerebral ischaemia; Huntington's disease; Multiple sclerosis; Nuerodegeneration; Parkinson's disease; Traumatic brain injury

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARICHIDONYL GLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BAY 38 7271; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS DERIVATIVE; CYTOKINE; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; GLYCEROL DERIVATIVE; LEVODOPA; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; PALMIDROL; PRS 211092; PRS 211095; RIMONABANT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN INJURY; BRAIN ISCHEMIA; CELL DEATH; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUNTINGTON CHOREA; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL LESION; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; RAT; REVIEW;

ANIMALS; CANNABINOIDS; HUMANS; NERVOUS SYSTEM DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036798247     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.10.1365     Document Type: Review

References (101)

1. ADAMS R. Marihuana. Harvey Lectures (1942) 37:168-197.
2. GAONI Y, MECHOULAM R: Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. (1964) 86:1646-1647.
3. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564.
4. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
5. GRUNDY RL RABUFFETTI M, BELTRAMO M: Cannabinoids and neuroprotection. Mol. Neurobiol. (2001) 24:29-51.
6. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
7. PORTER AC, SAUER JM, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. (2002) 301:1020-1024.
8. PERTWEE RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplmentarmed. (1999) 6(Suppl. 3):12-15.
9. PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert. Opin. Investig. Drugs (2000) 9:1553-1571.
10. HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87:1932-1936.
11. HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR, RICE KC: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. (1991) 11:563-583.
12. HERKENHAM M, LYNN AB, DE COSTA BR, RICHFIELD EK: Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. (1991) 547:267-274.
13. TSOU K, BROWN S, SANUDO-PENA MC, MACKIE K, WALKER JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 83:393-411.
14. FARQUHAR-SMITH WP, EGERTOVA M, BRADBURY EJ, MCMAHON SB, RICE AS, ELPHICK MR: Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell Neurosci. (2000) 15:510-521.
15. CROCI T, MANARA L, AUREGGI G et al.: In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol. (1998) 125:1393-1395.
16. GALIEGUE S, MARY S, MARCHAND J et al.: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. (1995) 232:54-61.
17. GERARD CM, MOLLEREAU C, VASSART G, PARMENTIER M: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. (1991) 279:129-134.
18. HOWLETT AC, QUALY JM, KHACHATRIAN LL: Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. (1986) 29:307-313.
19. BOUABOULA M, POINOT-CHAZEL C, BOURRIE, B et al.: Activation of mitogenactivated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. (1995) 312:637-641.
20. RUEDA D, GALVE-ROPERH I, HARO A, GUZMAN M: The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. (2000) 58:814-820.
21. MACKIE K, LAI Y, WESTENBROEK R, MITCHELL R: Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. (1995) 15:6552-6561.
22. DEADWYLER SA, HAMPSON RE, MU J, WHYTE A, CHILDERS S: Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. (1995) 2073:734-743.
23. MACKIE K, HILLE B: Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA (1992) 89:3825-3829.
24. GEBREMEDHIN D, LANGE AR, CAMPBELL WB, HILLARD CJ, HARDER DR: Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol. (1999) 276:H2085-H2093
25. GERDEMAN G, LOVINGER DM: CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. (2001) 85:468-471.
26. SZABO B, WALLMICHRATH I, MATHONIA P, PFREUNDTNER C: Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience (2000) 97:89-97.
27. AUCLAIR N, OTANI S, SOUBRIE P, CREPEL F: Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. (2000) 83:3287-3293.
28. MOLINA-HOLGADO F, LLEDO A, GUAZA C: Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport (1997) 8:1929-1933.
29. WAKSMAN Y, OLSON JM, CARLISLE SJ, CABRAL GA: The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. (1999) 288:1357-1366.
30. HILLARD CJ, MUTHIAN S, KEARN CS: Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. (1999) 459, 277-281.
31. KLEIN TW, NEWTON C, FRIEDMAN H: Cannabinoid receptors and immunity. Immunol. Today (1998) 19:373-381.
32. KLEIN TW, LANE B, NEWTON CA, FRIEDMAN H: The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. (2000) 225:1-8.
33. SMITH SR, TERMINELLI C, DENHARDT G: Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. (2000) 293:136-150.
34. GRUOL DL, SWEENEY DD, CONROY SM, TROTTER C, NETZEBAND JG, QIU Z: Cannabinoids alter neurotoxicity produced by interleukin-6 in central nervous system neurons. Adv. Fxp. Med. Biol. (1998) 437:231-240.
35. PUFFENBARGER RA, BOOTHE AC, CABRAL GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia (2000) 29:58-69.
36. JBILO O, DEROCQ JM, SEGUI M, LE FUR G, CASELLAS P: Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett. (1999) 448:273-277.
37. SACERDOTE P, MASSI P, PANERAI AE, PAROLARO D: In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. (2000) 109:155-163.
38. NEWTON C, KLEIN T, FRIEDMAN H: The role of macrophages in THC-induced alteration of the cytokine network. Adv. Exp. Med. Biol. (1998) 437:207-214.
39. BAINS JS, SHAW CA: Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. (1997) 25:335-358.
40. ESHHAR N, STRIEM S, KOHEN R, TIROSH O, BIEGON A: Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. (1995) 283:19-29.
41. HAMPSON AJ, GRIMALDI M, AXELROD J, WINK D: Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA (1998) 95:8268-8273.
42. MARSICANO G, MOOSMANN B, HERMANN H, LUTZ B, BEHLT C: Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. (2002) 80:448-456.
43. DOBLE A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. (1999) 81:163-221.
44. ESHHAR N, STRIEM S, BIEGON A: HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport (1993) 5:237-240.
45. NADLER V, MECHOULAM R, SOKOLOVSKY M: The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Nturosci. Lett. (1993) 162:43-45.
46. SKAPER SD, BURIANI A, DAL TOSO R et al.: The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA (1996) 93:3984-3989.
47. SHEN M, THAYER SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity, Mol. Pharmacol. (1998) 54:459-462.
48. ABOOD ME, RIZVI G, SALLAPUDI N, MCALLISTER SD: Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. (2001) 309:197-201.
49. HANSEN HH, SCHMID PC, BITTIGAU P et al.: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. (2001) 78:1415-1427.
50. VAN DER STELT M, VELDHUIS WB, BAR PR, VELDINK GA, VLIEGENTHART JF, NICOLAY K: Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. (2001) 21:6475-6479.
51. VAN DER STELT M, VELDHUIS WB, VAN HAAFTEN GW et al.: Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. (2001) 21:8765-8771.
52. NAGAYAMA T, SINOR AD, SIMON RP et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. (1999) 19:2987-2995.
53. SINOR AD, IRVIN SM, GREENBERG DA: Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. (2000) 278:157-160.
54. VERED M, BAR-JOSEPH A, BELAYEV L, BERKOVICH Y, BIEGON A: Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid. Acta Neurochir. Suppl. (Wien) (1994) 60:335-337.
55. BAR-JOSEPH A, BERKOVITCH Y, ADAMCHIK J, BIEGON A: Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. (1994) 23:125-135.
56. BELAYEV L, BUSTO R, ZHAO W, GINSBERG MD: HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke (1995) 26:2313-2319.
57. BELAYEV L, BAR-JOSEPH A, ADAMCHIK J, BIEGON A: HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol. Chem. Neuropathol. (1995) 25:19-33.
58. LEKER RR, SHOHAMI E, ABRAMSKY O, OVADIA H: Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J. Neurol. Sci. (1999) 162:114-119.
59. LOUW DF, YANG FW, SUTHERLAND GR: The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. (2000) 857:183-187.
60. MAULER F, MITTENDORF J, HORVATH E, DE VRY J: Characterization of the diarylether sulfonylester (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy)phenyl-4,4,4-trifluoro- l-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. (2002) 302:359-368.
61. IADECOLA C, ALEXANDER M: Cerebral ischemia and inflammation. Curr. Opin. Neurol. (2001) 14:89-94.
62. SHOHAMI E, NOVIKOV M, MECHOULAM R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma (1993) 10:109-119.
63. SHOHAMI E, GALLILY R, MECHOULAM R, BASS R, BEN-HUR T: Cytokine production in the brain following closed head injury-dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. (1997) 72:169-177.
64. NADLER V, BIEGON A, BEIT-YANNAI E, ADAMCHIK J, SHOHAMI E: 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res. (1995) 685:1-11.
65. PANIKASHVILI D, SIMEONIDOU C, BEN-SHABAT S et al.: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413:527-531.
66. PETRO DJ, ELLENBERGER CJ: Treatment of human spasticity with delta 9-tetrahydrocannabinol J. Clin. Pharmacol. (1981) 21:413S-416S.
67. CLIFFORD DB: Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. (1983) 13:669-671.
68. MARTYN CN, ILLIS LS, THOM J: Nabilone in the treatment of multiple sclerosis. Lancet (1995) 345:579.
69. MOLINA-HOLGADO F, MOLINA-HOLGADO E, GUAZA C: The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. (1998) 433:139-142.
70. WIRGUIN I, MECHOULAM R, BREUER A, SCHEZEN E, WEIDENFELD J, BRENNER T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1994) 28:209-214.
71. LYMAN WD, SONETT JR, BROSNAN CF, ELKIN R, BORNSTEIN MB: Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. (1989) 23:73-81.
72. ACHIRON A, MIRON S, LAVIE V, MARGALIT R, BIEGON A: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. (2000) 102:26-31.
73. BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84-87.
74. BAKER D, PRYCE G, CROXFORD JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. (2001) 15:300-302.
75. CADOGAN AK, ALEXANDER SP, BOYD EA, KENDALL DA: Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. (1997) 69:1131-1137.
76. MESCHLER JP, HOWLETT AC, MADRAS BK: Cannabinoid receptor agonist and antagonist effects on motor function in normal antl 1-methyl-4-phenyl-1, 2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Pychopharmacology (Berl) (2001) 156:79-85.
77. SILVERDALE MA, MCGUIRE S, MCINNES A, CROSSMAN AR, BROTCHIE JM: Striatal cannabirmid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. (2001) 169:400-406.
78. LASTRES-BECKER I, CEBEIRA M, DE CEBALLOS ML et al.: Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. (2001) 14:1827-1832.
79. DI MARZO V, HILL MP, BISOGNO T, CROSSMAN AR, BROTCHIE JM: Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. (2000) 14:1432-1438.
80. SIERADZAN KA, FOX SH, HILL M, DICK JP, CROSSMAN AR, BROTCHIE JM: Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology (2001) 57:2108-2111.
81. GLASS M: The role of cannabinoids in neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry (2001) 25:743-765.
82. RICHFIELD EK, HERKENHAM M: Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. (1994) 36:577-584.
83. CLASS M, DRAGUNOW M, FAULL RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 97:505-519.
84. DENOVAN-WRIGHT EM, ROBERTSON HA: Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience (2000) 98:705-713.
85. LASTRES-BECKER I, BERRENDERO F, LUCAS JJ et al.: Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB(1) receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. (2002) 929:236-242.
86. PAGE KJ, BESRET L, JAIN M, MONAGHAN EM, DUNNETT SB, EVERITT BJ: Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and muopioid receptor binding in the basal ganglia. Exp. Brain Res. (2000) 130:142-150.
87. LASTRES-BECKER I, FEZZA F, CEBEIRA M et al.: Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport (2001) 12:2125-2129.
88. LASTRES-BECKER I, HANSEN HH, BERRENDERO F: Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse (2002) 44:23-35.
89. GROTTA J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke (2002) 33:306-307.
90. LEES KR: Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke (2002) 33:308-309.
91. LEGOS JJ, TUMA RF, BARONE FC: Pharmacological interventions for stroke: failures and future. Expert. Opin. Investig. Drugs (2002) 11:603-614.
92. FEIGENBAUM JJ, BERGMANN F, RICHMOND SA et al.: Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. USA (1989) 86:9584-9587.
93. BREWSTER ME, POP E, FOLTZ RL et al: Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. (1997) 35:361-365.
94. PHARMOS CORP: Pharmos corporation reports 2002 first quarter results (2 May 2002):Press Release.
95. PHARMOS CORP: Pharmos reports significant brain recovery in stroke models using dexanabinol - new dexanabinol analogs seen as powerful neuroprotectants (7 July 2000):Press release.
96. GW PHARMACEUTICALS PLC: Annual report and accounts for the year ended 30 September 2001 (30 September 2001): Annual report.
97. BAYER AG: Drug development pipeline: New projects in development at Bayer (1 February 2002):Company communication.
98. KEARN CS, HILLARD CJ: Rat microglial cells express the peripheral type cannabinoid receptor (CB2) which is negatively coupled to adenylate cyclase. International Cannabinoid Research Society (1997):Abstract.
99. BREIVOGEL CS, GRIFFIN G, DI MARZO V, MARTIN BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. (2001) 60:155-163.
100. JARAI Z, WAGNER JA, VARGA K et al.: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA (1999) 96:14136-14141.
101. HAJOS N, LEDENT C, FREUND TF: Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience (2001) 106:1-4.